Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BP 1003

X
Drug Profile

BP 1003

Alternative Names: BP-1003; Liposomal Stat-3

Latest Information Update: 05 Sep 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action RNA interference; STAT3 transcription factor expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Breast cancer; Ovarian cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Sep 2024 Bio-Path Holdings expects to file an IND application for BP 1003 for Solid tumours
  • 15 Apr 2024 Bio-Path Holdings has patent protection for P-ethoxy nucleic acids for STAT3 inhibition in Australia
  • 21 Nov 2023 Preclinical development in Pancreatic-cancer is still ongoing in USA (IV, Infusion) (Bio-Path Holdings pipeline, November 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top